Overview

Preoperative Treatment With Cetuximab and/or IMC-A12

Status:
Completed
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to give cetuximab and/or IMC-A12 before surgery for squamous cell carcinoma of the head and neck, in order to learn if these study drugs may cause changes in biomarkers. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to a reaction to study treatment. The safety of the study treatments will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Eli Lilly and Company
ImClone LLC
Treatments:
Cetuximab